New reduced drinking goals in alcohol pharmacotherapy trials: a novel public-private effort and FDA approval process

Heavy alcohol use is a major public health problem leading to considerable morbidity and mortality, including increased risk of heart disease, stroke, liver pathology, and many cancers. Despite the recognized health and social consequences of excess alcohol consumption and increasing knowledge of th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Anton, Raymond F. (VerfasserIn) , O’Malley, Stephanie S. (VerfasserIn) , Mann, Karl (VerfasserIn) , Silverman, Bernard L. (VerfasserIn)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: September 17, 2025
In: JAMA psychiatry
Year: 2025, Jahrgang: 82, Heft: 12
ISSN:2168-6238
DOI:10.1001/jamapsychiatry.2025.2515
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamapsychiatry.2025.2515
Volltext
Verfasserangaben:Raymond F. Anton, Stephanie S. O’Malley, Karl Mann, Bernard L. Silverman

MARC

LEADER 00000caa a2200000 c 4500
001 1938083148
003 DE-627
005 20260202174927.0
007 cr uuu---uuuuu
008 251009s2025 xx |||||o 00| ||eng c
024 7 |a 10.1001/jamapsychiatry.2025.2515  |2 doi 
035 |a (DE-627)1938083148 
035 |a (DE-599)KXP1938083148 
035 |a (OCoLC)1559712801 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 11  |2 sdnb 
100 1 |a Anton, Raymond F.  |d 19XX-  |e VerfasserIn  |0 (DE-588)1378571932  |0 (DE-627)1938084098  |4 aut 
245 1 0 |a New reduced drinking goals in alcohol pharmacotherapy trials  |b a novel public-private effort and FDA approval process  |c Raymond F. Anton, Stephanie S. O’Malley, Karl Mann, Bernard L. Silverman 
264 1 |c September 17, 2025 
300 |a 1159-1160$t2 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 09.10.2025 
520 |a Heavy alcohol use is a major public health problem leading to considerable morbidity and mortality, including increased risk of heart disease, stroke, liver pathology, and many cancers. Despite the recognized health and social consequences of excess alcohol consumption and increasing knowledge of the neuroscience behind the development and maintenance of alcohol use disorder (AUD), few medications have been approved by regulatory agencies for its treatment. To address this gap, the Alcohol Clinical Trials Initiative (ACTIVE) was formed in 2012 after an initial meeting attended by academic experts, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the US Food and Drug Administration (FDA), and pharmaceutical companies to discuss ways to enhance drug development for AUD treatment. The goal of ACTIVE has been to evaluate and improve AUD clinical trial methods in a data-based manner that might inform regulatory guidance. Support for ACTIVE was funded by the pharmaceutical industry (over time by approximately 19 companies) with in-kind support and attendance by the FDA and NIAAA. As such, a public-private partnership was initiated consistent with the goals of the FDA Critical Path Initiative meant to benefit public health by improving and streamlining clinical trials. 
700 1 |a O’Malley, Stephanie S.  |e VerfasserIn  |4 aut 
700 1 |a Mann, Karl  |d 1948-  |e VerfasserIn  |0 (DE-588)120426455  |0 (DE-627)080667872  |0 (DE-576)187088012  |4 aut 
700 1 |a Silverman, Bernard L.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t JAMA psychiatry  |d Chicago, Ill. : AMA, 2013  |g 82(2025), 12  |h Online-Ressource  |w (DE-627)734675100  |w (DE-600)2698864-1  |w (DE-576)378915096  |x 2168-6238  |7 nnas  |a New reduced drinking goals in alcohol pharmacotherapy trials a novel public-private effort and FDA approval process 
773 1 8 |g volume:82  |g year:2025  |g number:12  |g extent:1159-1160$t2  |a New reduced drinking goals in alcohol pharmacotherapy trials a novel public-private effort and FDA approval process 
856 4 0 |u https://doi.org/10.1001/jamapsychiatry.2025.2515  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext  |7 1 
951 |a AR 
992 |a 20251009 
993 |a Editorial 
994 |a 2025 
998 |g 120426455  |a Mann, Karl  |m 120426455:Mann, Karl  |d 60000  |e 60000PM120426455  |k 0/60000/  |p 3 
999 |a KXP-PPN1938083148  |e 4783487316 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"given":"Raymond F.","family":"Anton","role":"aut","display":"Anton, Raymond F."},{"given":"Stephanie S.","family":"O’Malley","role":"aut","display":"O’Malley, Stephanie S."},{"given":"Karl","family":"Mann","role":"aut","display":"Mann, Karl"},{"role":"aut","display":"Silverman, Bernard L.","given":"Bernard L.","family":"Silverman"}],"relHost":[{"disp":"New reduced drinking goals in alcohol pharmacotherapy trials a novel public-private effort and FDA approval processJAMA psychiatry","note":["Gesehen am 02.12.2025"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"formerly Archives of general psychiatry","title":"JAMA psychiatry","title_sort":"JAMA psychiatry"}],"recId":"734675100","origin":[{"dateIssuedKey":"2013","publisherPlace":"Chicago, Ill.","dateIssuedDisp":"2013-","publisher":"AMA"}],"id":{"eki":["734675100"],"zdb":["2698864-1"],"issn":["2168-6238"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"issue":"12","text":"82(2025), 12","volume":"82","year":"2025","extent":"1159-1160$t2"},"pubHistory":["70.2013 -"]}],"title":[{"title_sort":"New reduced drinking goals in alcohol pharmacotherapy trials","title":"New reduced drinking goals in alcohol pharmacotherapy trials","subtitle":"a novel public-private effort and FDA approval process"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1001/jamapsychiatry.2025.2515"],"eki":["1938083148"]},"physDesc":[{"extent":"1159-1160$t2 S."}],"note":["Gesehen am 09.10.2025"],"name":{"displayForm":["Raymond F. Anton, Stephanie S. O’Malley, Karl Mann, Bernard L. Silverman"]},"recId":"1938083148","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"September 17, 2025"}]} 
SRT |a ANTONRAYMONEWREDUCED1720